Product
Carboplatin
Aliases
Blastocarb, Carboplat, Carboplatin AUC, Carboplatin AUC2 (38 other aliases)
Name
Carboplatin
Target
DNA
FDA Approved
Yes
Ema approved
Status
0
363 clinical trials
1 organization
1 drug
8 abstracts
398 indications
1 document
Indication
Non Small Cell Lung Cancer MetastaticIndication
Lung CancerIndication
EGFR Gene MutationIndication
CancerIndication
Cervical CancerIndication
Small Cell Lung CancerIndication
Solid TumorsIndication
Triple-negative Breast CancerIndication
HER2-positive Early Breast CancerIndication
Non-small-cell Lung CancerIndication
Non-squamous non-small cell lung cancerIndication
Anaplastic Pleomorphic XanthoastrocytomaIndication
Angiocentric GliomaIndication
Chordoid Glioma of Third VentricleIndication
GangliocytomaIndication
gangliogliomaIndication
Anaplastic GangliogliomaIndication
Gangliocytoma of the CerebellumIndication
Papillary Glioneuronal TumorIndication
Rosette-forming Glioneuronal TumorIndication
Central NeurocytomaIndication
Extraventricular NeurocytomaIndication
Cerebellar EpineurocytomaIndication
cancerIndication
Non-Small Cell LungIndication
Recurrent Epithelial OvarianIndication
Fallopian or Peritoneal CarcinomaIndication
Pilocytic AstrocytomaIndication
Giant Cell AstrocytomaIndication
Pleomorphic XanthoastrocytomaIndication
Bladder CancerIndication
MyelosuppressionIndication
NeutropeniaIndication
Breast NeoplasmsIndication
Recurrent head and neck cancerIndication
Metastatic Head and Neck CancerIndication
Neoplasms by SiteIndication
Lung DiseasesIndication
Respiratory Tract DiseaseIndication
BronchogenicIndication
Bronchial NeoplasmsIndication
AdenocarcinomaIndication
NeoplasmsIndication
EGFR Exon 20 MutationIndication
EGFR Exon 20 Insertion MutationIndication
Antineoplastic AgentsIndication
Metastatic Lung CancerIndication
Brain MetastasesIndication
EGFR mutated non-small cell lung cancerIndication
Advanced Non-small-cell Lung CancerIndication
Endometrial CancerIndication
Extensive-stage Small-cell Lung CancerIndication
Extensive-stage Small Cell Lung CancerIndication
NSCLCIndication
Squamous Cell Carcinoma of Head and NeckIndication
Small Cell Lung CarcinomaIndication
HER2-expressingIndication
Small Cell Lung Cancer RecurrentIndication
Neuroendocrine CarcinomaIndication
Respiratory Tract NeoplasmsIndication
Diffuse AstrocytomaIndication
Anaplastic AstrocytomaIndication
AstrocytomaIndication
OligodendrogliomaIndication
ChildhoodIndication
GlioblastomaIndication
Epithelial Ovarian CancerIndication
Ovarian CancerIndication
Ovarian Serous AdenocarcinomaIndication
Fallopian Tube NeoplasmsIndication
Fallopian Tube AdenocarcinomaIndication
Peritoneal CancerIndication
Peritoneal NeoplasmsIndication
Ovarian Neoplasm EpithelialIndication
lung cancerIndication
Solid TumorIndication
Colorectal CancerIndication
CholangiocarcinomaIndication
Stomach CancerIndication
Palpable Subcutaneous Malignant LesionsIndication
Renal Cell CarcinomaIndication
MelanomaIndication
Primary Peritoneal CancerIndication
Fallopian tube cancerIndication
Breast CancerIndication
Lung AdenocarcinomaIndication
Small Cell LungIndication
Endometrial NeoplasmsIndication
Extensive Stage-Small Cell Lung CancerIndication
Triple-Negative Breast CancerIndication
MesotheliomaIndication
malignantIndication
Head and Neck CancerIndication
Triple Negative Metastatic Breast CancerIndication
CarboplatinIndication
PaclitaxelIndication
Advanced or Metastatic Solid TumorsIndication
HR+ Breast CancerIndication
CCNE1 AmplificationIndication
Esophageal adenocarcinomaIndication
CarcinosarcomaIndication
Squamous CellIndication
Recurrent Non-Small Cell Lung CarcinomaIndication
Non-Small Cell Lung CarcinomaIndication
Stage IIIA Non-Small Cell Lung CancerIndication
Stage IIIB Non-Small Cell Lung CancerIndication
Stage IV Non-Small Cell Lung CancerIndication
Advanced CancerIndication
Metastatic Urothelial CancerIndication
Metastatic Non-small Cell Lung CancerIndication
B-Cell Non-Hodgkin LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
High-grade Ovarian CancerIndication
Advanced Solid TumorIndication
Non-Small-Cell Lung CancerIndication
Advanced Solid TumorsIndication
KRAS p.G12CIndication
non-small cell lung cancerIndication
Mature B-Cell Non-Hodgkin LymphomaIndication
Neuroendocrine TumorsIndication
Non-small Cell Lung Cancer Stage IVIndication
Metastatic Non Small Cell Lung CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
Pancreatic CancerIndication
Prostate CancerIndication
Bile Duct CancerIndication
Advanced/Metastatic TumorsIndication
Ovarian Epithelial CancerIndication
Advanced Solid TumoursIndication
KRASIndication
NRASIndication
Lung Cancer Stage IVIndication
Malignant Solid TumorIndication
Pancreatic Ductal AdenocarcinomaIndication
Non-small-cell LungIndication
Triple Negative Breast CancerIndication
lymphomaIndication
Non-HodgkinIndication
PD-1Indication
Squamous non-small cell lung cancerIndication
Malignant Pleural MesotheliomaIndication
Myelodysplastic SyndromesIndication
LeukemiaIndication
MyelomonocyticIndication
ChronicIndication
myeloidIndication
AcuteIndication
Chronic Kidney DiseaseIndication
Liver DiseaseIndication
Recurrent Non-small Cell Lung CancerIndication
Uterine sarcomaIndication
Squamous-Cell Non-Small-Cell Lung CancerIndication
KEAP1 Gene MutationIndication
NRF2 gene mutationIndication
NFE2L2 Gene MutationIndication
Endometrial Cancer RecurrentIndication
Lung Cancer RecurrentIndication
Non-small Cell Lung Cancer MetastaticIndication
Non-small Cell CarcinomaIndication
triple-negative breast cancerIndication
Urothelial Carcinoma Associated 1 RNAIndication
HumanIndication
Non-small Cell Lung CarcinomaIndication
Resectable Non-small Cell Lung CancerIndication
Lung CarcinomaIndication
Non-small-cell Lung CarcinomaIndication
B-Cell MalignanciesIndication
Non-Small-Cell Lung CarcinomaIndication
Metastatic Non-Small Cell Lung CancerIndication
Stage III NSCLCIndication
Gynecologic NeoplasmsIndication
pharmacokineticsIndication
Non-Squamous Non-Small Cell Lung CancerIndication
Cancer of Unknown Primary SiteIndication
Extensive-Stage Small Cell Lung CancerIndication
RecurrentIndication
Ovarian CarcinomaIndication
small cell lung cancerIndication
Extensive StageIndication
Ovarian Cancer by FIGO StageIndication
Stage IV Ovarian CancerIndication
Stage IIIIndication
fallopian tube carcinomaIndication
Primary Peritoneal CarcinomaIndication
Non-small-cell-lung-cancerIndication
Metastatic Solid TumorsIndication
Head and Neck NeoplasmsIndication
Uterine Corpus Cancer, Stage IAIndication
Uterine Corpus Cancer, Stage IBIndication
Uterine Corpus CancerIndication
Stage IVA Uterine Corpus CancerIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Oropharyngeal CancerIndication
Basaloid Squamous Cell CarcinomaIndication
Anal Canal Cloacogenic CarcinomaIndication
Anal Squamous Cell CarcinomaIndication
Anal CancerIndication
Stage IV Anal Cancer AJCC v8Indication
Stage IIIB Lung CancerIndication
Stage IV Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
solid tumorIndication
Protocol SpecificIndication
Bladder Urothelial CarcinomaIndication
Stage II Non-Small Cell Lung CancerIndication
Performance StatusIndication
NSCLC with RET fusionIndication
Lung NeoplasmIndication
Wilms TumorIndication
Breast Cancer Stage IVIndication
Thoracic NeoplasmsIndication
Bronchial DiseasesIndication
Germ Cell and EmbryonalIndication
nerve tissueIndication
Esophageal squamous cell carcinomaIndication
Programmed Cell Death-1 (PD1)Indication
Programmed Cell Death 1 Ligand 1 (PDL1)Indication
PD-L1Indication
Programmed Cell Death 1 Ligand 2 (PDL2)Indication
PD-L2Indication
Biliary Tract NeoplasmsIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Recurrent Lung Non-Small Cell CarcinomaIndication
Breast Cancer, Stage IVIndication
Triple-Negative Breast CarcinomaIndication
Esophageal CancerIndication
Stage IIIA Gastric Cancer AJCC v7Indication
GanglioneuroblastomaIndication
Resectable NeuroblastomaIndication
NeuroblastomaIndication
Pediatric CancerIndication
AdultIndication
HRDIndication
Estrogen Receptor-Negative Breast CancerIndication
HER2/Neu NegativeIndication
Recurrent Uterine CancerIndication
Metastatic CancerIndication
Castration-Resistant Prostate CarcinomaIndication
Extensive-stage small cell lung cancerIndication
Metastatic Triple-Negative Breast CancerIndication
Progesterone Receptor NegativeIndication
Progesterone Receptor Positive TumorIndication
Breast Cancer, Stage IIIndication
Stage IIA Breast CancerIndication
Triple-negative Breast CarcinomaIndication
Diffuse Large B-cell LymphomaIndication
MetastasisIndication
GliosarcomaIndication
Glioblastoma MultiformeIndication
IDH-wildtypeIndication
Estrogen Receptor NegativeIndication
Metastatic Squamous Cell CarcinomaIndication
Oral Cavity Squamous Cell CarcinomaIndication
oropharynx squamous cell carcinomaIndication
Hypopharyngeal Squamous Cell CarcinomaIndication
Laryngeal Squamous Cell CarcinomaIndication
Stage II Breast CancerIndication
Stage IIB Breast CancerIndication
HER2-Positive Breast CarcinomaIndication
Breast CarcinomaIndication
Stage IIIA Breast CancerIndication
Stage IIIB Breast CancerIndication
Stage IV Breast Cancer AJCC v8Indication
Stage III Ovarian CancerIndication
Salivary Gland CancerIndication
Recurrent Salivary Gland CancerIndication
Adenoid Cystic CarcinomaIndication
Breast carcinomaIndication
Endometrioid AdenocarcinomaIndication
Brenner TumorIndication
Ovarian Clear Cell AdenocarcinofibromaIndication
Endometrioid ovarian adenocarcinomaIndication
Ovarian Mucinous AdenocarcinomaIndication
Ovarian Seromucinous CarcinomaIndication
Ovarian Transitional Cell CarcinomaIndication
Ovarian Undifferentiated CarcinomaIndication
Primary Peritoneal Serous AdenocarcinomaIndication
Fallopian Tube CancerIndication
Stage IIIA Fallopian Tube Cancer AJCC v7Indication
Ovarian Cancer AJCC Stage IIIA v6 and v7Indication
Acute Myeloid LeukemiaIndication
Atypical chronic myeloid leukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Essential ThrombocythemiaIndication
Papillary SerousIndication
Clear Cell Endometrial CancerIndication
Unknown primary tumorIndication
Malignant NeoplasmIndication
Hepatocellular CarcinomaIndication
Intrahepatic CholangiocarcinomaIndication
Stage IIIA Hepatocellular CarcinomaIndication
intrahepatic cholangiocarcinomaIndication
Neoadjuvant TherapyIndication
MyelofibrosisIndication
Polycythemia VeraIndication
Recurrent Acute Myeloid LeukemiaIndication
Breast Cancer (HER2-positive)Indication
Breast NeoplasmIndication
Breast Cancer Stage IIIndication
Breast Cancer Stage IIIIndication
Hormone Receptor-positive Breast CancerIndication
Stage III Breast CancerIndication
Fallopian Tube CarcinomaIndication
Ovarian Endometrioid TumorIndication
Ovarian High Grade Serous AdenocarcinomaIndication
Platinum-Sensitive Ovarian CarcinomaIndication
Oropharyngeal Squamous Cell CarcinomaIndication
Oropharyngeal Carcinoma AJCC v8Indication
Squamous Cell CarcinomaIndication
Hypopharyngeal CarcinomaIndication
Carcinoma of Unknown PrimaryIndication
Esophageal cancerIndication
Liver FailureIndication
Testicular CancerIndication
Metastatic Malignant NeoplasmIndication
Kidney FailureIndication
Thymic CarcinomaIndication
Gastric Esophageal CancerIndication
Brain CancerIndication
Laryngeal CancerIndication
Hypopharyngeal Carcinoma (Stage IVA)Indication
Stage IVA Laryngeal CancerIndication
Stage IVA Lip and Oral Cavity CancerIndication
Stage IVB Laryngeal Cancer AJCC v8Indication
Lip and Oral Cavity CancerIndication
Fallopian Tube Serous AdenocarcinomaIndication
Low-grade serous ovarian carcinomaIndication
Low Grade Serous AdenocarcinomaIndication
Stage III Ovarian Cancer AJCC v8Indication
Fallopian Tube Cancer, Stage IV, AJCC v8Indication
Primary Peritoneal Cancer (Stage IV)Indication
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung CancerIndication
Lung Non-Small Cell CarcinomaIndication
Stage III Lung CancerIndication
Non-Hodgkin lymphomaIndication
SarcopeniaIndication
ToxicityIndication
RetinoblastomaIndication
Testicular seminomaIndication
Stage IIIndication
Squamous Cell Carcinoma of LarynxIndication
Retinal NeoplasmIndication
Low Grade Serous Adenocarcinoma of OvaryIndication
Limited-stage Small-cell Lung CancerIndication
Non-Small Cell Lung Cancer stage IIBIndication
Stage IIIA Non-small Cell Lung CancerIndication
Adenocarcinoma of the LungDrug
TQB2450Indication
high-grade gliomaIndication
Pleural mesotheliomaIndication
Gastric CancerClinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Double-blind, Phase 3 Study of the Efficacy and Safety of Sindilizumab Combined With Chemotherapy or Placebo Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (ORIENT-99)Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-10-25
Clinical trial
A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-07-05
Clinical trial
A Randomized, Open-Label, Multicenter, Phase 2, Umbrella Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations With and Without Chemotherapy as Neoadjuvant Treatment in Chinese Patients With Resectable Stage II to IIIA Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer - SCope-D1Status: Terminated, Estimated PCD: 2023-08-30
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)Status: Active (not recruiting), Estimated PCD: 2022-10-03
Clinical trial
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-08-29
Clinical trial
A Randomized, Double-blind, Parallel-controlled Study Comparing the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (SIBP04) and Bevacizumab Injection (Avastin) in Combination With Paclitaxel and Carboplatin Respectively in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer.Status: Completed, Estimated PCD: 2022-12-26
Clinical trial
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase III, Randomized, Single-blind Study Comparing the Efficacy, Safety, and Immunogenicity of SIBP-01 and CN-Trastuzumab Combination With Docetaxel and Carboplatin in Patients With Early or Locally Advanced Her2 Positive Breast CancerStatus: Completed, Estimated PCD: 2023-04-26
Clinical trial
An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)Status: Active (not recruiting), Estimated PCD: 2023-07-06
Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)Status: Active (not recruiting), Estimated PCD: 2026-07-14
Clinical trial
Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-04-10
Clinical trial
A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2019-12-15
Clinical trial
A Phase I/III, Multi-center, Randomized, Double-blind Study of BAT3306 Plus Chemotherapy Versus Keytruda® Plus Chemotherapy to Evaluate Pharmacokinetics, Efficacy, and Safety in Participants With Stage IV Non-squamous Non-small Cell Lung Cancer.Status: Not yet recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and AtezolizumabStatus: Active (not recruiting), Estimated PCD: 2025-04-18
Clinical trial
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)Status: Terminated, Estimated PCD: 2023-04-07
Clinical trial
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic AlterationsStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2019-02-25
Clinical trial
A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)Status: Active (not recruiting), Estimated PCD: 2023-06-12
Clinical trial
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)Status: Completed, Estimated PCD: 2022-06-15
Clinical trial
Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase Ib/II Clinical Trial of AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)Status: Active (not recruiting), Estimated PCD: 2020-12-31
Clinical trial
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase III, Randomized，Double-blind Placebo-controlled Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-stage Small Cell Lung CancerStatus: Completed, Estimated PCD: 2023-10-13
Clinical trial
A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based TherapyStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLCStatus: Completed, Estimated PCD: 2021-12-06
Clinical trial
A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-ExpressingStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)Status: Active (not recruiting), Estimated PCD: 2024-08-11
Clinical trial
An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)Status: Recruiting, Estimated PCD: 2026-11-20
Clinical trial
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)Status: Completed, Estimated PCD: 2021-08-23
Clinical trial
A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)Status: Active (not recruiting), Estimated PCD: 2020-01-27
Clinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsStatus: Active (not recruiting), Estimated PCD: 2024-08-23
Clinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-09-26
Clinical trial
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung CancerStatus: Terminated, Estimated PCD: 2023-02-17
Clinical trial
A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)Status: Completed, Estimated PCD: 2019-04-01
Clinical trial
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)Status: Active (not recruiting), Estimated PCD: 2023-02-02
Clinical trial
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial CancerStatus: Active (not recruiting), Estimated PCD: 2020-01-27
Clinical trial
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)Status: Terminated, Estimated PCD: 2022-12-27
Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)Status: Active (not recruiting), Estimated PCD: 2022-11-10
Clinical trial
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2026-10-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of Neoadjuvant Treatment With Tislelizumab (BGB-A317, Anti-PD-1 Antibody) or Placebo Plus Platinum-Based Doublet Chemotherapy Followed By Adjuvant Tislelizumab or Placebo in Resectable Stage II or IIIA Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast CancerStatus: Completed, Estimated PCD: 2019-04-05
Clinical trial
A Randomized, Multicenter, Open-Label Phase II Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination Toripalimab or Sequence Chemotherapy in Participants With HR-negative, HER2 Low-expressing Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2011-10-10
Clinical trial
A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2019-08-16
Clinical trial
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-21
Clinical trial
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)Status: Active (not recruiting), Estimated PCD: 2025-03-05
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin MonotherapyStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-05-01
Clinical trial
Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin MonotherapyStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-Blind, Phase 3 Study of MK-7684A in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-11-10
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 1 Clinical Study to Evaluate the Bioavailability of Pembrolizumab Via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2026-09-26
Clinical trial
A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese ParticipantsStatus: Recruiting, Estimated PCD: 2026-10-07
Clinical trial
A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2020-09-30
Clinical trial
A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2013-01-04
Clinical trial
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Status: Active (not recruiting), Estimated PCD: 2018-07-19
Clinical trial
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)Status: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical CarcinomaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerStatus: Completed, Estimated PCD: 2021-03-12
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2023-09-21
Clinical trial
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)Status: Active (not recruiting), Estimated PCD: 2023-05-23
Clinical trial
A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2026-04-09
Clinical trial
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study"Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)Status: Completed, Estimated PCD: 2021-10-18
Clinical trial
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)Status: Recruiting, Estimated PCD: 2027-07-06
Clinical trial
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-23
Clinical trial
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)Status: Recruiting, Estimated PCD: 2027-02-22
Clinical trial
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-05-08
Clinical trial
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-07-26
Clinical trial
A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2026-11-01
Clinical trial
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) PatientsStatus: Completed, Estimated PCD: 2014-11-01
Clinical trial
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor AberrationsStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Multicenter, Open-label, ph 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)Status: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression LevelsStatus: Recruiting, Estimated PCD: 2030-01-16
Clinical trial
A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-03
Clinical trial
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C MutationStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase InhibitorsStatus: Not yet recruiting, Estimated PCD: 2028-09-12
Clinical trial
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)Status: Recruiting, Estimated PCD: 2028-03-29
Clinical trial
A Phase 1b, Multicenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of CC-90011 Given in Combination With Cisplatin and Etoposide in First Line, Extensive Stage Subjects With Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-26
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2026-07-06
Clinical trial
Phase 1/2a, First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT411 as a Monotherapy in Patients With Solid Tumors and in Combination With Atezolizumab, Carboplatin and Etoposide in Patients With Chemotherapy-naïve Extensive-stage Small Cell Lung Cancer (ES-SCLC)Status: Active (not recruiting), Estimated PCD: 2024-01-19
Clinical trial
A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2016-06-24
Clinical trial
A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Japanese Patients With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J)Status: Not yet recruiting, Estimated PCD: 2026-07-15
Clinical trial
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).Status: Recruiting, Estimated PCD: 2027-08-17
Clinical trial
LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
DAREON™-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)Status: Recruiting, Estimated PCD: 2025-11-05
Clinical trial
DAREONᵀᴹ-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung CarcinomaStatus: Recruiting, Estimated PCD: 2025-08-20
Clinical trial
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2027-10-15
Clinical trial
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial CarcinomaStatus: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2028-04-30
Clinical trial
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2039-02-13
Clinical trial
A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)Status: Recruiting, Estimated PCD: 2028-12-22
Clinical trial
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2020-10-08
Clinical trial
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-06
Clinical trial
Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of Bevacizumab (Mabscale LLC, Russia) + Paclitaxel + Carboplatin to Avastin® + Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)Status: Recruiting, Estimated PCD: 2025-12-23
Clinical trial
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2026-12-15
Clinical trial
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.Status: Active (not recruiting), Estimated PCD: 2025-05-06
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-09-06
Clinical trial
A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic TumorsStatus: Active (not recruiting), Estimated PCD: 2024-10-05
Clinical trial
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2027-05-14
Clinical trial
A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Open-Label, Phase Ib/II Study of AK119 and AK112 With or Without Chemotherapy in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) TreatmentStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2020-01-17
Clinical trial
Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, MTD/RP2D, and Antitumor Activity of ARTS-021 as a Single Agent and in Combination Therapy in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)Status: Recruiting, Estimated PCD: 2027-10-22
Clinical trial
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast CancerStatus: Active (not recruiting), Estimated PCD: 2016-12-19
Clinical trial
A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-30
Clinical trial
A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.Status: Active (not recruiting), Estimated PCD: 2025-02-19
Clinical trial
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion MutationsStatus: Active (not recruiting), Estimated PCD: 2026-02-20
Clinical trial
A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-29
Clinical trial
A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Multicenter, Open Phase Ib Study of the Safety and Efficacy of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2019-01-07
Clinical trial
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-04-04
Clinical trial
A Randomized, Double-blind, Phase 3 Bridging Study Evaluating the Safety and Efficacy of ABP 215 Compared With Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerStatus: Withdrawn, Estimated PCD: 2022-11-13
Clinical trial
A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)Status: Recruiting, Estimated PCD: 2024-08-06
Clinical trial
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2021-06-16
Clinical trial
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - MAURISStatus: Completed, Estimated PCD: 2023-07-13
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-13
Clinical trial
AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118) Combined With Tislelizumab (VDT482) Plus Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Chemotherapy as First-line Therapy for Participants With Advanced Triple Negative Breast Cancer (TNBC)Status: Withdrawn, Estimated PCD: 2029-07-17
Clinical trial
A Single-arm, Open-label, and Multicenter Phase Ⅱ Study Designed to Evaluate the Efficacy and Safety of Rulonilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Status: Not yet recruiting, Estimated PCD: 2024-10-25
Clinical trial
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)Status: Completed, Estimated PCD: 2021-06-15
Clinical trial
A Randomized, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Sintilimab (IBI308) in Combination With Gemcitabine and Platinum-Based Chemotherapy vs. Placebo in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Treatment for Patients With Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) (ORIENT-12)Status: Completed, Estimated PCD: 2020-03-25
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)Status: Completed, Estimated PCD: 2019-12-02
Clinical trial
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural MesotheliomaStatus: Completed, Estimated PCD: 2020-03-25
Clinical trial
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2021-06-11
Clinical trial
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)Status: Completed, Estimated PCD: 2018-04-03
Clinical trial
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Completed, Estimated PCD: 2021-05-26
Clinical trial
A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast CancerStatus: Completed, Estimated PCD: 2020-02-27
Clinical trial
An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Phase II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetic Characteristics of PM8002 Injection Combined With Standard Chemotherapy in the First-line Treatment of Subjects With Inoperable Malignant MesotheliomaStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic ImpairmentStatus: Completed, Estimated PCD: 2021-03-19
Clinical trial
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125.Status: Terminated, Estimated PCD: 2012-02-01
Clinical trial
An Open-label Phase 2 Study of QL1706 Plus Carboplatin and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-02-01
Clinical trial
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced MyelosuppressionStatus: Terminated, Estimated PCD: 2022-07-30
Clinical trial
A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) TherapyStatus: Recruiting, Estimated PCD: 2025-05-20
Clinical trial
A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2022-07-05
Clinical trial
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung CancerStatus: Completed, Estimated PCD: 2018-04-24
Clinical trial
Evaluating the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for First-line Treatment of Patient With Advanced Endometrial Cancer or Sarcoma of Uterus: a Multi-center, Open-label, Randomized Controlled, Phase II Clinical Trial.Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Multi-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-antigen Autologous Immune Cell Injection (MASCT-I) in Patients With Advanced Solid Tumor, and to Preliminarily Evaluate the Anti-tumor Efficacy of MASCT-I Alone, in Combination With Chemical Drugs, and in Combination With PD1 AntibodyStatus: Recruiting, Estimated PCD: 2023-07-01
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First RelapseStatus: Terminated, Estimated PCD: 2012-12-31
Clinical trial
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-18
Clinical trial
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-05-28
Clinical trial
A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid TumorStatus: Completed, Estimated PCD: 2014-04-01
Clinical trial
TAK-676 Alone and in Combination(s) With Carboplatin, 5-Fluorouracil, and Paclitaxel in Patients With Head and Neck Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Completed, Estimated PCD: 2022-02-08
Clinical trial
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)Status: Completed, Estimated PCD: 2021-12-06
Clinical trial
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)Status: Terminated, Estimated PCD: 2021-11-05
Clinical trial
A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-12-31
Clinical trial
An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsStatus: Completed, Estimated PCD: 2023-06-28
Clinical trial
A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2023-03-08
Clinical trial
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination With Other Anti-Cancer Therapy in Subjects With Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select MalignanciesStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial CarcinomaStatus: Completed, Estimated PCD: 2020-04-29
Clinical trial
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)Status: Active (not recruiting), Estimated PCD: 2023-08-11
Clinical trial
Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)Status: Terminated, Estimated PCD: 2023-10-03
Clinical trial
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)Status: Completed, Estimated PCD: 2021-04-12
Clinical trial
A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (INSIGHT)Status: Completed, Estimated PCD: 2017-12-12
Clinical trial
A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CarcinomaStatus: Completed, Estimated PCD: 2016-11-07
Clinical trial
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLCStatus: Not yet recruiting, Estimated PCD: 2025-09-28
Clinical trial
A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2020-02-04
Clinical trial
A Rollover Study to Provide Continued Treatment With M6620Status: Active (not recruiting), Estimated PCD: 2023-12-15
Clinical trial
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLCStatus: Active (not recruiting), Estimated PCD: 2021-09-08
Clinical trial
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)Status: Completed, Estimated PCD: 2017-11-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on ImmunotherapyStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
AdvanTIG-306: A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118/BGB-A1217) Combined With Tislelizumab (VDT482/BGB-A317) Plus Platinum-based Doublet Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Platinum-based Doublet Chemotherapy as First-line Therapy for Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Status: Withdrawn, Estimated PCD: 2027-12-24
Clinical trial
A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian CancerStatus: Terminated, Estimated PCD: 2022-04-25
Clinical trial
A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of KN046 in Patients With Advanced Non-small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-07-30
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Status: Active (not recruiting), Estimated PCD: 2025-06-18
Clinical trial
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-10-25
Clinical trial
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-02-14
Clinical trial
An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial CancerStatus: Recruiting, Estimated PCD: 2023-08-08
Clinical trial
Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor TherapyStatus: Completed, Estimated PCD: 2022-01-20
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase Ш Clinical Study to Evaluate the Efficacy and Safety of First-line Treatment With SG001 Plus Chemotherapy±Bevacizumab Versus Placebo Plus Chemotherapy±Bevacizumab for PD-L1 Positive (CPS≥1) Women With Recurrent, or Metastatic Cervical CancerStatus: Not yet recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase Ib/II Clinical Trial to Evaluate the Anti-tumor Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Anti-PD-1/L1 Antibody and Chemotherapy as First-line Treatment in Extensive-stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-01-24
Clinical trial
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2019-07-18
Clinical trial
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)Status: Active (not recruiting), Estimated PCD: 2023-08-11
Clinical trial
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 MutationStatus: Recruiting, Estimated PCD: 2025-08-11
Clinical trial
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Terminated, Estimated PCD: 2019-05-03
Clinical trial
A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).Status: Completed, Estimated PCD: 2023-06-21
Clinical trial
Phase Ib Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Etoposide and Carboplatin for the First-line Treatment of Patients With Extensive Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube CancerStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)Status: Completed, Estimated PCD: 2021-06-24
Clinical trial
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2022-07-29
Clinical trial
KANDOVA - A Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination With Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: An Open-Label, Multicenter Dose Escalation Study With an Expansion Cohort in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ StudyStatus: Withdrawn, Estimated PCD: 2025-02-01
Clinical trial
A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)Status: Not yet recruiting, Estimated PCD: 2025-11-15
Clinical trial
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)Status: Active (not recruiting), Estimated PCD: 2026-11-26
Clinical trial
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi TreatmentStatus: Not yet recruiting, Estimated PCD: 2028-04-11
Clinical trial
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical CancerStatus: Completed, Estimated PCD: 2022-01-20
Clinical trial
A Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of PM8002(Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With EGFR-mutant Advanced Non-squamous NSCLC Who Have Failed to EGFR-TKI TreatmentStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2 Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy for Patients With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-11-12
Clinical trial
A Randomized, Multicenter, Open-Label, Phase Ib Study to Evaluate Efficacy, Safety and Tolerability of IBI110 in Combination With Sintilimab Plus Etoposide and Platinum or Carboplatin in Patients With Untreated Extensive-Stage Small Cell Lung CancerStatus: Completed, Estimated PCD: 2023-02-16
Clinical trial
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial CarcinomaStatus: Recruiting, Estimated PCD: 2024-01-01
Abstract
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.Org: University of Kansas Cancer Center, GZA ANTWERP BELGIUM, Texas Oncology, University of Kansas Medical Center, University of Kansas Medical Center Department of Internal Medicine,
Clinical trial
A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-09-28
Clinical trial
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase I Study of Xevinapant With Radiation and Concurrent Carboplatin and Paclitaxel in Patients Ineligible for Cisplatin With Locoregionally Advanced Squamous Cell Carcinoma of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2027-10-01
Clinical trial
FIGO 2018 Stage IB2 (> 2 to ≤4cm) Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve FertilityStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory StudyStatus: Completed, Estimated PCD: 2023-09-15
Clinical trial
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.Status: Active (not recruiting), Estimated PCD: 2022-10-14
Clinical trial
Atezolizumab, Pertuzumab and Trastuzumab With Chemotherapy as Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)Status: Active (not recruiting), Estimated PCD: 2026-12-15
Clinical trial
'ADVANCE' (A Pilot Trial) ADjuVANt Chemotherapy in the Elderly: Developing and Evaluating Lower-Toxicity Chemotherapy Options for Older Patients With Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-11-10
Clinical trial
Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal JunctionStatus: Completed, Estimated PCD: 2020-08-07
Clinical trial
A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical StagingStatus: Terminated, Estimated PCD: 2019-10-01
Clinical trial
A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Carboplatin to Prevent Progression After Serologic Detection of Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Trial of Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx CancerStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2017-10-31
Clinical trial
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer PatientsStatus: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2022-09-07
Clinical trial
Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICIStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube CarcinomaStatus: Completed, Estimated PCD: 2015-01-01
Clinical trial
Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Primary Bladder TumorsStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)Status: Not yet recruiting, Estimated PCD: 2026-09-08
Clinical trial
Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2019-10-24
Clinical trial
Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-06
Clinical trial
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-06-19
Clinical trial
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
A Phase 1b Study of Ensartinib in Combination With Platinum-Based Chemotherapy and Bevacizumab in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2027-09-23
Clinical trial
NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial)Status: Recruiting, Estimated PCD: 2026-09-18
Clinical trial
A Prospective, Single-armed Study to Evaluate the Efficacy and Safety of Neoadjuvant Pembrolizumab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma PatientsStatus: Completed, Estimated PCD: 2023-03-30
Clinical trial
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric CardiaStatus: Completed, Estimated PCD: 2021-07-01
Clinical trial
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2025-06-22
Clinical trial
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesStatus: Terminated, Estimated PCD: 2023-10-16
Clinical trial
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2022-08-04
Clinical trial
Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-04
Clinical trial
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Open-label, Prospective Phase III Clinical Study to Compare Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) With Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Alone as Salvage Therapy in Patients With Primary Refractory or Relapsed Diffuse Large B-cell Lymphoma (DLBCL)Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 ExpressionStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 2 Open-Label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Patients With Metastatic Advanced Stage Ovarian CancerStatus: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLCStatus: Recruiting, Estimated PCD: 2026-04-28
Clinical trial
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian CancerStatus: Completed, Estimated PCD: 2022-05-01
Clinical trial
High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Rescue for Neuroblastoma: Standard of Care ConsiderationsStatus: Completed, Estimated PCD: 2023-05-30
Clinical trial
Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent GlioblastomaStatus: Recruiting, Estimated PCD: 2024-09-10
Clinical trial
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-10-31
Clinical trial
Efficacy and Safety of Tislelizumab With Platinum Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Initially Unresectable Stage III Non-small Cell Lung Cancer: A Single-arm, Phase II TrialStatus: Recruiting, Estimated PCD: 2024-02-29
Clinical trial
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the UterusStatus: Completed, Estimated PCD: 2018-08-17
Clinical trial
Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLCStatus: Active (not recruiting), Estimated PCD: 2021-05-09
Clinical trial
A Phase 1B Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase 2 Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2027-08-01
Clinical trial
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and CarboplatinStatus: Completed, Estimated PCD: 2024-01-01
Clinical trial
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262Status: Active (not recruiting), Estimated PCD: 2015-12-01
Clinical trial
Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Recruiting, Estimated PCD: 2026-08-30
Clinical trial
Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian CancerStatus: Completed, Estimated PCD: 2023-06-01
Clinical trial
A Multicentre, Open-label, Randomised Trial of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerStatus: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or PembrolizumabStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)Status: Active (not recruiting), Estimated PCD: 2023-05-31
Clinical trial
Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial CancerStatus: Completed, Estimated PCD: 2019-12-13
Clinical trial
A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS TrialStatus: Completed, Estimated PCD: 2021-05-04
Clinical trial
A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2021-02-10
Clinical trial
An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast Cancer（NeoSACT）Status: Recruiting, Estimated PCD: 2023-08-31
Clinical trial
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2021-06-19
Clinical trial
Effectiveness of Atezolizumab in Large Cell Neuroendocrine Carcinoma of the Lung and the Value of miR21 and miR-375 as BiomarkersStatus: Completed, Estimated PCD: 2022-08-01
Clinical trial
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic CholangiocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBCStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
EFFECT-neo: A Prospective, Open-label, Multicenter Phase III Study to Evaluate Efficacy and Safety of Pembrolizumab Combined With Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCCStatus: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
A Feasibility Study of De-escalation of Chemotherapy in Patients With Early-Stage HER2 Positive Breast CancerStatus: , Estimated PCD: 2025-06-01
Clinical trial
A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast CancerStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Pilot Window of Opportunity Study Evaluating Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy Followed by Evaluation of Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy and Abequolixron (RGX-104) in Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-19
Clinical trial
A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC PatientsStatus: Completed, Estimated PCD: 2023-11-10
Clinical trial
TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)Status: Not yet recruiting, Estimated PCD: 2029-06-01
Clinical trial
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)Status: Active (not recruiting), Estimated PCD: 2019-12-18
Clinical trial
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2030-11-01
Clinical trial
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2017-11-10
Clinical trial
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/PaclitaxelStatus: Completed, Estimated PCD: 2022-11-19
Clinical trial
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C MutationStatus: Not yet recruiting, Estimated PCD: 2026-09-30
Clinical trial
Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2023-06-19
Clinical trial
Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical StudyStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumStatus: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain MetastasesStatus: Terminated, Estimated PCD: 2022-07-15
Clinical trial
Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer: a Single Arm, Open Label, Phase II Clinical StudyStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-05-03
Clinical trial
A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Phase II Trial of Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-Related Oropharynx CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Pilot Study of the Safety and Feasibility of Administering Concurrent Chemotherapy and Accelerated Hypofractionated Radiation Therapy in the Treatment of Medically Inoperable T2A-T4 N0 Non-small Cell Lung Cancer.Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE StudyStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Induced and Concurrent Serplulimab Plus Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for Stage III-IVA Cervical Cancer: a Prospective, Multicenter, Randomized, Open Controlled Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2025-05-31
Clinical trial
Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerStatus: Completed, Estimated PCD: 2022-06-16
Clinical trial
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-01-27
Clinical trial
SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II StudyStatus: , Estimated PCD: 2026-02-01
Clinical trial
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell LymphomasStatus: Completed, Estimated PCD: 2018-08-27
Clinical trial
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase Ib Open-Label Study of LB-100 in Combination With Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage Small Cell Lung CarcinomaStatus: Recruiting, Estimated PCD: 2026-03-09
Clinical trial
Phase II Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018Status: Recruiting, Estimated PCD: 2035-01-20
Clinical trial
A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm SeminomasStatus: Recruiting, Estimated PCD: 2025-09-06
Clinical trial
A Single-arm, Multi-institutional, Phase 2 Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx CancersStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Conservative Treatments of RetinoblastomaStatus: Active (not recruiting), Estimated PCD: 2023-01-01
Clinical trial
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial)Status: Recruiting, Estimated PCD: 2029-09-22
Clinical trial
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer: an Open-label, Non-randomized Controlled, Phase II, Single-center StudyStatus: Not yet recruiting, Estimated PCD: 2027-04-15
Clinical trial
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Neoadjuvant Tislelizumab and Platinum-Based Doublet Chemotherapy in Stage II-IIIB EGFR-Mutated Lung Adenocarcinoma With PD-L1 Positive Expression -- A Phase II Study (DuoVitality)"Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)Status: Active (not recruiting), Estimated PCD: 2023-03-11
Clinical trial
A Phase 3, Prospective，Multicenter, Randomized Open-Label Trial to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Chemotherapy Followed By Surgery Versus Up-Front Surgery as Treatment for Resectable Head And Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
Nivolumab With Chemotherapy in Pleural Mesothelioma After SurgeryStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Newly Diagnosed Stage Ⅲ Unresectable Non-small Cell Lung Cancer: a Open-label, Single-arm Prospective Clinical TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
THERApy De-escalation for TESTicular CancerStatus: Recruiting, Estimated PCD: 2027-05-01
Document
DailyMed Label: PARAPLATINOrganization
Accord BioPharma Inc.